Last reviewed · How we verify
Jadenu
At a glance
| Generic name | Jadenu |
|---|---|
| Also known as | deferasirox tablets |
| Sponsor | DisperSol Technologies, LLC |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Boxed warnings
- WARNING: RENAL FAILURE, HEPATIC FAILURE, and GASTROINTESTINAL HEMORRHAGE Renal Failure JADENU can cause acute renal failure and death, particularly in patients with comorbidities and those who are in the advanced stages of their hematologic disorders. Evaluate baseline renal function prior to starting or increasing JADENU dosing in all patients. JADENU is contraindicated in adult and pediatric patients with eGFR less than 40 mL/min/1.73 m 2 . Measure serum creatinine in duplicate prior to initia
Common side effects
- Diarrhea
- Vomiting
- Nausea
- Abdominal pain
- Skin rashes
- Increases in serum creatinine
- Rash
Serious adverse events
- Drug-induced hepatitis
- Elevations in serum glutamic-pyruvic transaminase (SGPT)/ALT greater than 5 times ULN
- Henoch Schönlein purpura
- Glycosuria/proteinuria
- Increases in serum creatinine greater than 33% above baseline
Key clinical trials
- Evaluation of the Quality of Life in Patients With Chronic Iron Overload Due to Hemoglobinopathies in Greece.
- Combination of Thalidomide and Hydroxyuria in Transfusion Dependent Thalasemmia (PHASE2)
- Phase II Study of Resistant Potato Starch Plus Deferasirox to Improve Outcomes in Patients Undergoing Allogeneic Stem Cell Transplantation (PHASE2)
- Early Screening and Treatment of Heart Complication in Sickle Cell Disease (PHASE2)
- Evaluating the Effect of N-Acetyl Cysteine and Alpha Lipoic Acid in Patients With Beta Thalassemia (PHASE3)
- Risk Factors and Measures to Prevent Liver and Pancreas Complications in Pediatric Patients After HSCT
- Treatment of Transfusion-dependent Nonsevere Aplastic Anemia With Luspatercept: a Multicenter Prospective Clinical Study (NA)
- Observational Study Towards the Impact of Newly Started Treatment in MDS on QoL
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |